Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing
Neuphoria Therapeutics has agreed to be acquired by Scancell Holdings in an all-share merger, where Neuphoria shareholders will receive Scancell ADSs at an exchange ratio of 37.77199 and Contingent Value Rights for partnered assets. The combined entity will list on Nasdaq under the ticker SCLT, utilizing up to $89 million in secured financing—including equity placements and debt from BlackRock—to fund Scancell's Phase 3 trial for iSCIB1+.
Key figures
- Exchange ratio
- 37.77199
- Uk placing usd
- 12000000
- Retail offer usd
- 3000000
- Debt financing usd
- 25000000
- Pro forma cash usd
- 79100000
- Financing total usd
- 89000000
- Private placement usd
- 39100000
- Neuphoria ownership percent
- 13.7% to 14.5%
- Scancell cash usd
- 79100000
- Share consolidation ratio
- 10:1
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.